Intensity Therapeutics Files S-1 for Securities Registration
Ticker: INTS · Form: S-1 · Filed: Apr 22, 2025 · CIK: 1567264
| Field | Detail |
|---|---|
| Company | Intensity Therapeutics, Inc. (INTS) |
| Form Type | S-1 |
| Filed Date | Apr 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: s-1, registration, sec-filing, biotech
TL;DR
Intensity Therapeutics just filed an S-1, looks like they're raising capital soon.
AI Summary
Intensity Therapeutics, Inc. filed an S-1 registration statement on April 22, 2025, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with principal offices in Shelton, CT, operates in the biological products sector. Lewis H. Bender serves as President, CEO, and Chairman.
Why It Matters
This S-1 filing indicates Intensity Therapeutics is preparing to offer new securities to the public, which could provide capital for its operations and growth, potentially impacting its stock value and investor base.
Risk Assessment
Risk Level: medium — S-1 filings are typically associated with companies seeking to raise capital, which can involve inherent risks related to market reception and future performance.
Key Numbers
- 333-286683 — SEC File Number (Identifies the specific SEC registration)
- 25858621 — Film Number (Internal SEC processing number)
Key Players & Entities
- INTENSITY THERAPEUTICS, INC. (company) — Registrant
- April 22, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- Shelton, CT (location) — Principal Executive Offices
- Lewis H. Bender (person) — President, Chief Executive Officer and Chairman
- Securities Act of 1933 (legislation) — Governing Act for Registration
- Mintz, Levin, Cohn, Ferris, Glo (company) — Legal Counsel
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement under the Securities Act of 1933, indicating Intensity Therapeutics, Inc. is preparing to offer securities to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted on April 22, 2025.
Who is the President, CEO, and Chairman of Intensity Therapeutics, Inc.?
Lewis H. Bender holds the positions of President, Chief Executive Officer, and Chairman of Intensity Therapeutics, Inc.
Where are Intensity Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Intensity Therapeutics, Inc. are located at 1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779.
What is the Standard Industrial Classification code for Intensity Therapeutics, Inc.?
The Primary Standard Industrial Classification Code for Intensity Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on April 22, 2025 by Lewis H. Bender regarding INTENSITY THERAPEUTICS, INC. (INTS).